Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sten Stovall

London, UK
Sten Stovall is a London-based editor and writer with 40 years of experience in the field of journalism, including more than 20 years with Reuters and eight years with The Wall Street Journal/Dow Jones Newswires. He also has wide radio and television reporting experience and a solid network of contacts in the biopharma world. Sten is part of our team of specialist reporters, generating insightful features and analysis about R&D, product development, regulatory issues and industry trends for publications such as "The Pink Sheet", Scrip and IN VIVO.
Set Alert for Articles By Sten Stovall

Latest From Sten Stovall

Alnylam and Regeneron Plan 50/50 Gene R&D Pact To Find NASH RNAi Drugs

Duo to equally share development costs and profits from any candidates emerging from their RNAi discovery pact.

Commercial Companies

Zealand Rushes Out Good Safety News On Phase III Dasiglucagon Rescue Pen

Early results confirm dasiglucagon's safety profile with no treatment-induced or treatment-boosted anti-drug antibodies.

Clinical Trials Commercial

Roche Gains With Tecentriq IMpower131 NSCLC Data, But For How Long?

Roche is "first to market" with Phase III Tecentriq data in first-line squamous NSCLC setting, but analysts note Merck and Bristol are not far behind.

Analysis Clinical Trials

Alzheon IPO To Fund New Phase III Trialling Of Failed Alzheimer's Drug

Alzheon tells prospective investors it believes beta-amyloid blocker ALZ-801 can succeed in pivotal trials by treating APOE4 subgroup.

Analysis Clinical Trials

Arix Says Latest Equity Raising May Be Last For Some Time As Exit Options Loom

Arix Bioscience's £87m equity raising brings to £250m the amount it has raised for incubating life sciences start-ups – but it might be the last for a while if portfolio 'exits' start generating cash, its CEO tells Scrip.

Analysis Business Strategies

Diurnal's £11m Placing To Promote First Product Launch And Pipeline

Diurnal's CEO Martin Whitaker says 2018 promises to be transformational for the late-stage endocrinology company.

Financing Business Strategies
See All